Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)
Clinical trial NCT04046224 · COMPLETED
Trial details
- NCT number
- NCT04046224
- Sponsor
- Sangamo Therapeutics
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-07-23
- Primary completion
- 2025-04-10
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.